aTYR PHARMA INC
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
ATYR$7.56-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this Annual Report.
- Index list to Financial Statements:
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 73 |
| Consolidated Balance Sheets | 75 |
| Consolidated Statements of Operations | 76 |
| Consolidated Statements of Comprehensive Loss | 77 |
| Consolidated Statements of Stockholders’ Equity | 78 |
| Consolidated Statements of Cash Flows | 79 |
| Notes to Consolidated Financial Statements | 80 |
- Financial Statement Schedules.
Schedules have been omitted as all required information has been disclosed in the consolidated financial statements and related footnotes.
- Exhibits.
The Exhibits listed in the Exhibit Index are filed as a part of this Annual Report.
EXHIBIT INDEX
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Title | Form | File No. | Exhibit | Filing Date |
| 3.1 | Restated Certificate of Incorporation of the Registrant | 10-Q | 001-37378 | 3.1 | November 14, 2022 |
| 3.2 | Certificate of Amendment to Restated Certificate of Incorporation of the Registrant | 8-K | 001-37378 | 3.1 | June 28, 2019 |
| 3.3 | Certificate of Amendment to Restated Certificate of Incorporation of the Registrant | 10-Q | 001-37378 | 3.3 | May 12, 2020 |
| 3.4 | Certificate of Amendment to Restated Certificate of Incorporation of the Registrant | 8-K | 001-37378 | 3.1 | May 4, 2021 |
| 3.5 | Certificate of Amendment to Restated Certificate of Incorporation of the Registrant | 8-K | 001-37378 | 3.1 | April 29, 2022 |
| 3.6 | Certificate of Amendment to Restated Certificate of Incorporation of the Registrant | 8-K | 001-37378 | 3.1 | May 19, 2023 |
| 3.7 | Amended and Restated Bylaws of the Registrant | 10-Q | 333-203272 | 3.6 | November 14, 2022 |
| 4.1 | Specimen Common Stock Certificate | S-1/A | 333-203272 | 4.1 | April 27, 2015 |
| 4.2 | Description of Common Stock of the Registrant | 10-K | 001-37378 | 4.6 | March 14, 2024 |
| 10.1* | 2015 Stock Option and Incentive Plan, as amended | 8-K | 001-37378 | 10.1 | May 6, 2025 |
| 10.2* | Forms of agreement under 2015 Stock Option and Incentive Plan | S-1/A | 333-203272 | 10.2 | April 27, 2015 |
| 10.3 | Form of Indemnification Agreement entered into between the Registrant and its directors | S-1/A | 333-203272 | 10.12 | April 27, 2015 |
| 10.4 | Form of Indemnification Agreement entered into between the Registrant and its officers | S-1/A | 333-203272 | 10.13 | April 27, 2015 |
| 10.5* | Senior Executive Cash Incentive Bonus Plan | 8-K | 001-37378 | 10.1 | January 29, 2016 |
| 10.6* | Executive Severance and Change in Control Policy | 10-K | 001-37378 | 10.16 | March 30, 2016 |
| 10.7* | Registrant’s Non-Qualified Stock Option Agreement for Non-Plan Inducement Grant | 10-Q | 001-37378 | 10.1 | November 14, 2016 |
| 10.8* | Employment Agreement, dated November 1, 2017, by and between the Registrant and Sanjay S. Shukla, M.D., M.S. | 10-Q | 001-37378 | 10.4 | November 14, 2017 |
| 10.9* | Employment Offer Letter by and between the Registrant and Jill M. Broadfoot, dated July 16, 2018 | 8-K | 001-37378 | 10.1 | August 1, 2018 |
| 10.10* | Employment Offer Letter by and between the Registrant and Ms. Nancy Krueger, Esq., dated October 7, 2014 | 10-Q | 001-37378 | 10.2 | May 14, 2019 |
| 10.11† | Collaboration and License Agreement by and between the Registrant and Kyorin Pharmaceutical Co., Ltd., dated January 6, 2020 | S-1/A | 333-235951 | 10.21 | February 3, 2020 |
| 10.12* | First Amendment to Employment Agreement dated February 5, 2021, by and the between the Registrant and Sanjay S. Shukla, M.D., M.S. | 10-K | 001-37378 | 10.19 | March 24, 2021 |
| 10.13* | aTyr Pharma, Inc. 2015 Employee Stock Purchase Plan, as amended | 8-K | 001-37378 | 10.2 | April 29, 2022 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Title | Form | File No. | Exhibit | Filing Date |
| 10.14* | aTyr Pharma, Inc. 2022 Inducement Plan, as amended | 10-Q | 001-37378 | 10.2 | August 7, 2025 |
| 10.15* | Forms of Grant Notice and Stock Option Agreement under aTyr Pharma, Inc. 2022 Inducement Plan | 10-Q | 001-37378 | 10.4 | May 10, 2022 |
| 10.16 | Open Market Sale AgreementSM dated April 22, 2022 by and between the Registrant and Jefferies LLC | 8-K | 001-37378 | 1.1 | April 22, 2022 |
| 10.17 | Amendment No. 1 Open Market Sale AgreementSM dated December 23, 2024 by and between the Registrant and Jefferies LLC | 8-K | 001-37378 | 1.1 | December 23, 2024 |
| 10.18 | Lease dated May 12, 2022, by and between the Registrant and San Diego Creekside, LLC | 8-K | 001-37378 | 10.1 | May 16, 2022 |
| 10.19 | First Amendment to Lease Between the Registrant and San Diego, Creekside, LLC, dated April 8, 2024 | 10-Q | 001-37378 | 10.1 | May 2, 2024 |
| 10.20* | Non-Employee Director Compensation Policy, as amended | 8-K | 001-37378 | 99.1 | December 12, 2024 |
| 14.1 | aTyr Pharma, Inc. Code of Business Conduct and Ethics, as amended | 8-K | 001-37378 | 14.1 | May 29, 2024 |
| 19.1 | aTyr Pharma, Inc. Statement of Company Policy on Insider Trading and Disclosure | 10-K | 001-37378 | 19.1 | March 13, 2025 |
| 19.2 | aTyr Pharma, Inc. Special Trading Procedures for Designated Individuals | 10-K | 001-37378 | 19.2 | March 13, 2025 |
| 21.1 | Subsidiaries of the Registrant | S-1 | 333-203272 | 21.1 | April 6, 2015 |
| 23.1 | Consent of Independent Registered Public Accounting Firm | — | — | — | Filed herewith |
| 97.1 | aTyr Pharma, Inc. Incentive Compensation Recoupment Policy | 10-K | 001-37378 | 97.1 | March 14, 2024 |
| 31.1 | Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 31.2 | Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 32.1# | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 32.2# | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 101.INS | Inline XBRL Instance Document | — | — | — | Filed herewith |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbases Document | — | — | — | Filed herewith |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Title | Form | File No. | Exhibit | Filing Date |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibits 101) | — | — | — | Filed herewith |
- Indicates a management contract or compensatory plan, contract or arrangement.
† Certain portions have been omitted because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or confidential.
The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Annual Report on Form 10-K), unless the Registrant specifically incorporates the foregoing information into those documents by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.